Cytokinetics announced this morning that the FDA has accepted 6-Minute Walk Test as an acceptable primary endpoint for ambulatory spinal muscular atrophy patients and recommended a global function score such as Hammersmith Functional Motor Scale - Extended as a secondary endpoint, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. The analyst reiterates an Overweight rating on Cytokinetics with a $12 price target. He points out the company will conduct additional Phase I studies of higher doses of reldesemtiv before returning to SMA patients.